Press release
Telix Pharmaceuticals Limited (NASDAQ: TLX) Investor Alert: Deadline in Lawsuit on January 9, 2026
A Deadline is coming up on January 9, 2026 in the lawsuit for certain investors in Telix Pharmaceuticals Limited (NASDAQ: TLX).
Investors who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX) have certain options and there are strict and short deadlines running. Deadline: January 9, 2026. Telix Pharmaceuticals Limited (NASDAQ: TLX) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Southern District of Indiana the plaintiff alleges on behalf of purchasers of Telix Pharmaceuticals Limited (NASDAQ: TLX) common shares between February 21, 2025 and August 28, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 21, 2025 and August 28, 2025, the defendants made false and/or misleading statements and/or failed to disclose that, the Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates, that the Defendants materials overstated the quality of Telix's supply chain and partners, and that as a result, defendants statements about Telix's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Telix Pharmaceuticals Limited (NASDAQ: TLX) Investor Alert: Deadline in Lawsuit on January 9, 2026 here
News-ID: 4341389 • Views: …
More Releases from Shareholders Foundation, Inc.
Long-Term Investors in Lantheus Holdings, Inc. (NASDAQ: LNTH) should contact the …
An investigation was announced for long-term investors in shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) concerning potential breaches of fiduciary duties by certain directors and officers of Lantheus Holdings, Inc..
Investors who are current long term investors in Lantheus Holdings, Inc. (NASDAQ: LNTH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Skye Bioscience, Inc. (NASDAQ: SKYE) Investor NOTICE: Deadline in Lawsuit on Jan …
A deadline is coming up on January 16, 2026 in the lawsuit filed for certain investors of Skye Bioscience, Inc. (NASDAQ: SKYE) over alleged securities laws violations by Skye Bioscience, Inc.
Investors who purchased shares of Skye Bioscience, Inc. (NASDAQ: SKYE) have certain options and there are strict and short deadlines running. Deadline: January 16, 2026. Skye Bioscience, Inc. (NASDAQ: SKYE) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Investigation announced for Long-Term Investors in shares of V.F. Corporation (N …
An investigation was announced for long-term investors in shares of V.F. Corporation (NYSE: VFC) concerning potential breaches of fiduciary duties by certain directors of V.F. Corporation.
Investors who are current long term investors in V.F. Corporation (NYSE: VFC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: VFC stocks…
Perrigo Company plc (NYSE: PRGO) Investor Alert: Deadline in Lawsuit on January …
A deadline is coming up on January 16, 2026 in the lawsuit filed for certain investors of Perrigo Company plc (NYSE: PRGO) over alleged securities laws violations by Perrigo Company plc.
Investors who purchased shares of Perrigo Company plc (NYSE: PRGO) have certain options and there are strict and short deadlines running. Deadline: January 16, 2026. Perrigo Company plc (NYSE: PRGO) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
More Releases for Telix
Radioligand Therapy Market Set for Dynamic Prospective as Key Players Novartis, …
The qualitative latest Research report (2025-2032) on the Radioligand Therapy Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
➤ Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/138432
Focused on…
Radionuclide Drug Conjugates Market Top Players - Telix Pharmaceuticals Limited, …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Radionuclide Drug Conjugates (RDCs) Market Size, Share & Trends Analysis Report By Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma, Others)- Market Outlook And Industry Analysis 2031"
The Global Radionuclide Drug Conjugates (RDCs) Market is expected to grow with a CAGR…
Radionuclide Drug Conjugates Market Key Players Analysis - Telix Pharmaceuticals …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Radionuclide Drug Conjugates (RDCs) Market Size, Share & Trends Analysis Report By Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma, Others)- Market Outlook And Industry Analysis 2031"
The Global Radionuclide Drug Conjugates (RDCs) Market is expected to grow with a CAGR…
Radiotheranostic Market Detailed In New Research Report 2025 | Novartis AG, Baye …
Radiotheranostic Market Analysis - 2025-2032:
Coherent Market Insights has released a new report titled "Radiotheranostic Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032 (Version 2025)." This report provides an in-depth analysis of the Radiotheranostic industry, featuring insights on market trends and performance. It also includes a thorough examination of competitors, regional dynamics, and the latest advancements within the market.
Coverage of the Radiotheranostic Market:
The report provides market size (2020 -…
Radioligand Therapy Market: Analysis by Trends, Technology, and Growth Opportuni …
The global radioligand therapy market reached US$ 1.79 billion in 2023 and is expected to reach US$ 14.36 million by 2031, growing at a CAGR of 29.0% during the forecast period 2024-2031.
Radioligand Therapy Market analysis, according to DataM Intelligence, offers more than just an overview, it investigates the underlying aspects of the sector. The study provides an overview, the research explores the hidden aspects of the sector, breaking down its…
Metastatic Prostate Cancer Treatment Market Size, Share, Trends, and Forecast: 2 …
The Metastatic Prostate Cancer Treatment Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Metastatic Prostate Cancer Treatment market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify…
